These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 2884588)
1. Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats. Hong M; Jenner P; Marsden CD Neuropharmacology; 1987; 26(2-3):237-45. PubMed ID: 2884588 [TBL] [Abstract][Full Text] [Related]
2. Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat. Hong M; Kilpatrick GJ; Jenner P; Marsden CD Neuropharmacology; 1987 Aug; 26(8):1061-9. PubMed ID: 2889161 [TBL] [Abstract][Full Text] [Related]
3. The effect of long-term treatment with amine-depleting drugs or chlorpromazine on alpha-adrenoreceptors and 5-HT2 receptors in the brain of the rat. Hong M; Roots EJ; Jenner P; Marsden CD Neuropharmacology; 1988 May; 27(5):519-27. PubMed ID: 2899303 [TBL] [Abstract][Full Text] [Related]
4. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. Reches A; Burke RE; Kuhn CM; Hassan MN; Jackson VR; Fahn S J Pharmacol Exp Ther; 1983 Jun; 225(3):515-21. PubMed ID: 6864517 [TBL] [Abstract][Full Text] [Related]
5. N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function. Lewis MH; Widerlöv E; Knight DL; Kilts CD; Mailman RB J Pharmacol Exp Ther; 1983 Jun; 225(3):539-45. PubMed ID: 6134814 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors. Vasse M; Protais P Neuropharmacology; 1989 Sep; 28(9):931-9. PubMed ID: 2554186 [TBL] [Abstract][Full Text] [Related]
7. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats. Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859 [TBL] [Abstract][Full Text] [Related]
8. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors. Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552 [TBL] [Abstract][Full Text] [Related]
9. Neurochemical and behavioral studies on the mode of action of oxypertine. Moroji T; Okuyama T; Hagino Y; Sekiguchi R Arzneimittelforschung; 1986 May; 36(5):804-8. PubMed ID: 2873819 [TBL] [Abstract][Full Text] [Related]
10. Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum. Thomas KL; Rose S; Jenner P; Marsden CD Biochem Pharmacol; 1992 Jul; 44(1):83-91. PubMed ID: 1321631 [TBL] [Abstract][Full Text] [Related]
11. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. Clow A; Theodorou A; Jenner P; Marsden CD Eur J Pharmacol; 1980 May; 63(2-3):135-44. PubMed ID: 6103813 [TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Magnusson O; Fowler CJ; Köhler C; Ogren SO Neuropharmacology; 1986 Feb; 25(2):187-97. PubMed ID: 2939362 [TBL] [Abstract][Full Text] [Related]
13. Tetrabenazine has properties of a dopamine receptor antagonist. Login IS; Cronin MJ; MacLeod RM Ann Neurol; 1982 Sep; 12(3):257-62. PubMed ID: 7137960 [TBL] [Abstract][Full Text] [Related]
14. Enhanced stereotyped response to amphetamine after pretreatment with small doses of molindone. Conway P; Uretsky NJ Neuropharmacology; 1983 May; 22(5):579-86. PubMed ID: 6308493 [TBL] [Abstract][Full Text] [Related]
15. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. Leysen JE; Eens A; Gommeren W; van Gompel P; Wynants J; Janssen PA J Pharmacol Exp Ther; 1988 Jan; 244(1):310-21. PubMed ID: 3336007 [TBL] [Abstract][Full Text] [Related]
16. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255 [TBL] [Abstract][Full Text] [Related]
17. Behavioural and biochemical studies on 6-methylamino-4,5,6,7-tetrahydrobenzothiazole (14.839JL), a new potent dopaminergic agonist. Ponzio F; Algeri S; Garattini S; Cioce V; Rusconi L; Sacchetti G; Manuel C; Notelle C; Duvert L; Legeai J Pharmacol Res Commun; 1987 Aug; 19(8):555-65. PubMed ID: 3432322 [TBL] [Abstract][Full Text] [Related]
18. Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine. Reches A; Hassan MN; Jackson VR; Fahn S Life Sci; 1983 Jul; 33(2):157-60. PubMed ID: 6865653 [TBL] [Abstract][Full Text] [Related]
19. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Clow A; Theodorou A; Jenner P; Marsden CD Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814 [TBL] [Abstract][Full Text] [Related]
20. Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats. Murugaiah K; Fleminger S; Hall MD; Theodorou A; Jenner P; Marsden CD Neuropharmacology; 1984 Jun; 23(6):599-609. PubMed ID: 6540376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]